Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.49 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.49 |
| ▸ | FABP7 | O15540 | 1/20 | 0.47 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14247589 | 0.91 | KMT2A (0.60) | KMT2AOPRD1EPHX2HDAC3HDAC4 | |
| SCHEMBL18740102 | 0.91 | KMT2A (0.63) | KMT2AOPRD1EPHX2HDAC3HDAC4 | |
| SCHEMBL30570803 | 0.91 | KMT2A (0.63) | KMT2AOPRD1EPHX2HDAC3HDAC4 | |
| SCHEMBL15548985 | 0.91 | KMT2A (0.66) | KMT2AOPRD1HDAC3HDAC4HDAC1 | |
| SCHEMBL19662823 | 0.87 | EPHX2 (0.63) | KMT2AOPRD1EPHX2FABP7FABP5 | |
| SCHEMBL3044412 | 0.86 | KMT2A (0.59) | KMT2AOPRD1EPHX2FABP7FABP5 | |
| SCHEMBL3177417 | 0.86 | KMT2A (0.62) | KMT2AOPRD1EPHX2FABP7FABP5 | |
| SCHEMBL4785263 | 0.85 | KMT2A (0.70) | KMT2AEPHX2HDAC1HDAC2 | |
| SCHEMBL23270799 | 0.85 | KMT2A (0.62) | KMT2AOPRD1EPHX2HDAC3HDAC4 | |
| SCHEMBL29397906 | 0.84 | KMT2A (0.81) | KMT2AOPRD1EPHX2FABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486372-B2 | Cyclic azapeptides as integrin markers and methods of using | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20120115811-A1 | PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | AMGEN INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-8043601-B2 | Cyclic azapeptides as integrin markers | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20110256057-A1 | Cyclic Azapeptides as Integrin Markers and Methods of Using | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110256057-A1 | Cyclic Azapeptides as Integrin Markers and Methods of Using | ITGAV, ITGB3, ITGA2B | KMT2A 3642/4885OPRD1 1525/4885EPHX2 3625/4885 |
| US-20120115811-A1 | PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | IAPP, INSR, AMY2A | KMT2A 2444/4885OPRD1 1959/4885EPHX2 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.